Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation (REACH 3)

Next Previous
X
Search
Trial Profile

A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation (REACH 3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Everolimus; Ibrutinib; Imatinib; Infliximab; Methotrexate; Mycophenolate mofetil; Pentostatin; Prednisone; Rituximab; Sirolimus
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH3
  • Sponsors Incyte Corporation; Novartis; Novartis Healthcare

    • Most Recent Events

    • 01 Dec 2024 Results from Japanese subgroup analysis of REACH3 study published in the International Journal of Hematology
    • 12 Dec 2023 Results assessing the final, long-term efficacy and safety outcomes from REACH3, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 28 Oct 2023 Results published in the Bone Marrow Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top